Targeting the MLL complex in castration resistant prostate cancer

Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castration resistant prostate cancer (CRPC). Although prior work focused on targeting AR directly, co-activators of AR signaling—which may represent new therapeutic targets—are relatively...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Malik, Rohit, Khan, Amjad P., Asangani, Irfan A., Cieślik, Marcin, Prensner, John R., Wang, Xiaoju, Iyer, Matthew K., Jiang, Xia, Borkin, Dmitry, Escara-Wilke, June, Stender, Rachell, Wu, Yi-Mi, Niknafs, Yashar S., Jing, Xiaojun, Qiao, Yuanyuan, Palanisamy, Nallasivam, Kunju, Lakshmi P., Krishnamurthy, Pranathi M., Yocum, Anastasia K., Mellacheruvu, Dattatreya, Nesvizhskii, Alexey I., Cao, Xuhong, Dhanasekaran, Saravana M., Feng, Felix Y., Grembecka, Jolanta, Cierpicki, Tomasz, Chinnaiyan, Arul M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390530/
https://ncbi.nlm.nih.gov/pubmed/25822367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3830
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados